Cellares is developing a solution to overcome the limitations associated with manufacturing cell therapies to make them more affordable and widely available to patients in need.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 05/06/21 | $82,000,000 | Series B |
Decheng Capital Eclipse Ventures Skyviews Life Science | undisclosed |
| 08/23/23 | $255,000,000 | Series C |
8VC Bristol Myers Squibb Decheng Capital DFJ Growth Eclipse Ventures Koch Disruptive Technologies Willett Advisors | undisclosed |
